3D printed medical devices are artificial devices that replace a missing body part or biological structure and are manufactured by laying successive layers of material using inputs from a digital 3D model. The main types of 3D printed medical devices are implants, surgical instruments, prosthetics, tissue engineering devices, and others. The 3D-printed implants are medical implants that are made using 3D printing technology to create complex geometries. These are made up of raw materials such as plastics, biomaterial inks, and metals and alloys. The technologies involved in 3D printed medical devices are fused deposition modeling, digital light processing, stereolithography, and selective laser melting. These provide applications in orthopedic, spinal, dental, hearing aids, and others that are used by end-users such as hospitals, diagnostics centres, academic institutions, and others. The 3D printed medical devices market research report is one of a series of new reports from The Business Research Company that provides 3D printed medical devices market statistics, including 3D printed medical devices industry global market size, regional shares, competitors with a 3D printed medical devices market share, detailed 3D printed medical devices market segments, market trends and opportunities, and any further data you may need to thrive in the 3D printed medical devices industry. This 3D printed medical devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global 3d printed medical devices market grew from $2.87 billion in 2022 to $3.57 billion in 2023 at a compound annual growth rate (CAGR) of 24.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The 3d printed medical devices market is expected to grow to $9.09 billion in 2027 at a CAGR of 26.3%. The increasing prevalence of osteoarthritis and similar musculoskeletal conditions is one of the major factors driving the growth of the 3D printed medical devices market. Osteoarthritis is a disorder that damages the joint cartilage and surrounding tissues causing pain, stiffness, and loss of joint function to the person affected by it. The 3D printing medical devices enable the creation of a replica of a patient's joint, which can provide surgeons with a crucial piece of information that might not be visible on a 2-dimensional scan. The chance of developing osteoarthritis increases with age. For instance, according to the US National Library of Medicine report, by 2040, it is estimated that approximately 78 million (26%) US adults aged 18 years and above will be projected to have doctor-diagnosed arthritis. Thereby driving the adoption of 3D printed medical devices, positively impacting the market growth. Biocompatibility issues related to 3D printed medical devices restrict the growth of the 3D printed medical devices market. Biocompatibility implies the properties that make a material or a device compatible with the human body. If the material used for the preparation of a 3D printed implant device is not compatible with the patients' biomechanics, then patients may suffer side effects such as abnormal growth of bone and bleeding. Among the most common metal used in the manufacturing of 3D printed medical devices is Titanium. Though Titanium offers reliability and accuracy in creating medical-grade products, some human bodies tend to reject titanium as its chemical composition can inhibit the bone and tissue from interacting with the implant. Apart from these other reasons which may contribute to the failure of metallic implants that are either caused by the material properties of the metal (e.g., high stiffness, high corrosion rate, and toxicity) itself or by the exposure of the bone to infected metal implants i.e., infection. The increasing use of 3D printing technology in the spine industry is one of the latest trends in the 3D printing medical devices market. The spine industry is adopting 3D printing to produce new innovative products that can promote bone ingrowth and improve implant fixation to spine bone, reducing the number of manufacturing steps, thereby making the 3D printing process more cost-effective in several cases. For instance, Medtronic launched its titanium 3D printed platform – TiONIC Technology. TiONIC Technology is a 3D printed technique that uses laser methods to create implants with enhanced surface textures. Artic-L is the first implant created by the company using TiONIC Technology. The implant is made up of titanium and is designed to be used by surgeons in spine surgery. In addition to that, K2M’s Lamellar, introduced its 3D Titanium Technology to create a 3D spinal implant. The 3D printing medical device using titanium technology uses an advanced 3D printing method to create structures that were once considered impractical with traditional manufacturing techniques. The implants use titanium powder and are associated with bone growth activity. Food and Drug Administration (FDA) has a Centre for Device and Radiological Health (CDRH) to regulate the firm which manufacture, repackage, relabel and/or import 3D printing medical devices in the US. FDA provides manufacturers with a draft with guidance that includes recommendations for device design, manufacturing, and testing considerations during the development of 3D printing medical devices. Section F of the 'Technical Considerations for Additive Manufactured Medical Device' draft, requires the manufacturers to evaluate the biocompatibility of the final finished device as described in the guidance "Use of International Standard ISO-10993". The guidelines also require the manufacturer of the 3D printing devices to mention the additional information in the label if any toxic chemical additives such as certain additives, catalysts, binding and curing agents, uncured monomers, and plasticizers are used in making 3D printing medical devices. In July 2020, Medtronic, an American Irish-domiciled medical device company acquired Medicrea International for an undisclosed amount. The acquisition of Medicrea expands Medtronic’s already deep portfolio as this adds to their spinal solution profile as the advent of new digital technology will offer the ability to custom spinal implants. Medicrea International is a spinal surgery company with 30+ FDA-approved spinal implant technologies that have been utilized in over 150,000 spinal surgeries to date. Major players in the 3D printed medical devices market are 3D Systems Corporation, EnvisionTEC, Stratasys Ltd., Arcam AB, Cyfuse Biomedical, Materialise NV, Organovo Holdings, EOS GmbH, FabRx Ltd., and Concept Laser. North America was the largest region in the 3D printed medical devices market in 2022. Western Europe was the second largest region in the global 3D printed medical devices market report. The regions covered in the global 3D printed medical devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the 3D printed medical devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The 3D printed medical devices market consists of sales of 3D printed prosthetics and implants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global 3D printed medical devices market is segmented - 1) By Type: Implants, Surgical instruments, Prosthetics, Tissue engineering devices, Other Types 2) By Application: Orthopedic, Spinal, Dental, Hearing Aids, Other Applications 3) By Technology: Fused Deposition Modelling, Digital Light Processing, Stereolithography, Selective Laser melting 4) By Raw Material: Plastics, Biomaterial inks, Metals and Alloys 5) By End User: Hospitals, Diagnostics Centres, Academic Institutions, Other End Users

Cell culture is a process for developing substrates for the safe production of viral vaccines. 3D cell culture is an in vitro technique wherein the cells can grow in an artificially created environment. The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The 3D cell culture technologies market research report is one of a series of new reports from The Business Research Company that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global 3d cell culture technologies market grew from $2.39 billion in 2022 to $2.83 billion in 2023 at a compound annual growth rate (CAGR) of 18.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The 3d cell culture technologies market is expected to grow from $5.65 billion in 2027 at a CAGR of 18.9%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. For instance, according to the Organ Procurement and Transplantation network, an American non-profit organization administering the organ transplantation in the US, 41,354 organ transplantations were performed in the United States in 2021 which was an increase of 5.9% as compared to 2020 and the number exceeded 40,000 mark for the first time ever.. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC., Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc., VWR International, LLC., WHEATON IndustriesInc., and Sartorius AG. North America was the largest region in the 3D cell culture technologies market in 2022. Western Europe was the second largest region in the 3D cell culture technologies market. The regions covered in the global 3D cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The global 3D cell culture technologies market is segmented - 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-based: Hydrogels, Polymeric scaffolds, Micropatterned Surface Microplates 4) By Scaffold-free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine

Biologics Market Definition

The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. Biologics products are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Biologics products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

Orthopedic biomaterials are materials intended to be inserted into the human body as constituents of devices designed to perform certain biological functions by either substituting or repairing various tissues, such as bones, cartilage, ligaments, tendons, and others. The orthopedic biomaterials market covered in this report is segmented by material type into ceramics and bioactive glasses, calcium phosphate cement, polymers, metal, and composites. Polymers are used as orthopedic biomaterials intended to be inserted into the human body as constituents. The various applications are orthopedic implants, joint replacement/reconstruction, bio-resorbable tissue fixation, orthobiologics, and viscosupplementation. These are used by various end-users such as hospitals, clinics, and others. The orthopedic biomaterials market research report is one of a series of new reports from The Business Research Company that provides orthopedic biomaterials market statistics, including orthopedic biomaterials industry global market size, regional shares, competitors with a orthopedic biomaterials market share, detailed orthopedic biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the orthopedic biomaterials industry. This orthopedic biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global orthopedic biomaterials market grew from $16.9 billion in 2022 to $18.62 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The orthopedic biomaterials market is expected to grow from $29.69 billion in 2027 at a CAGR of 12.4%. The rise in the incidence of musculoskeletal disorders is expected to drive the orthopedic biomaterials market. According to the World Health Organization (WHO) report, musculoskeletal conditions are the leading contributor to disability worldwide. About 20-33% of the population suffer from a musculoskeletal disability. Musculoskeletal disorders induce fractures, swelling, and discomfort in the joints, ligaments, and tendons that cause movement disabilities. The burden of musculoskeletal conditions is known to increase with age. The sustainable development goals (SDGs) and the Decade of Healthy Ageing 2020–2030 have called for increased global attention and action on musculoskeletal health. Biomaterials are used to treat these disorders. Hence, the incidence of musculoskeletal disorders is projected to drive the orthopedic biomaterials market. The high cost of conducting clinical trials is expected to hinder the biomaterials market growth. The orthopedic biomaterials are directly implanted in the body. Therefore, it is important to prove the safety and biocompatibility of these materials. However, the high cost of conducting clinical trials is acting as a major roadblock. The clinical studies are expensive and time-consuming due to the number of tests required, and the length of each test. The investment of resources, time, and funding grows with successive stages. Additional costs are associated with the result of the trials at different phases. For instance, the cost of a failed phase 3 trial is not just the cost associated with the trial itself but the cost of all prior trials as well as the cost of lost time pursuing a potentially viable alternative or repeating the steps. Therefore, the high cost of conducting clinical trials is expected to impact the orthopedic biomaterials market. 3D printing of orthopedic implants is one of the recent developments in the orthopedic biomaterials market. 3D printing technology is used to produce a large range of medical equipment, such as those with complicated structures or characteristics to suit a patient’s particular anatomy. 3D printing of orthopedic implants enables the design of more natural anatomical shapes, as well as the design of porous bone replacement scaffolds that can be easily integrated into the design of the implant. This allows natural bone regeneration to generate higher reliability of the implant. 3D printing of orthopedic implants is a trend in the orthopedic biomaterial market that is attracting many players. For instance, Evonik, a Germany-based chemical company has invested in Meditool, a Chinese-based 3d printed implant start-up that produces models and implants by using polyether ketone (PEEK) polymer supplied by Evonik. In November 2020, Olympus, a Japanese medical technology company, acquired FH Ortho for an undisclosed amount. The acquisition would help Olympus to grow in the field of orthopaedic minimally invasive surgery. FH Ortho is a France based orthopaedics company. Major players in the orthopedic biomaterials market are Zimmer Biomet Holdings Inc., Stryker Corporation, Victrex PLC (Invibio Ltd.), Globus Medical Inc., CAM Bioceramics B.V., Heraeus Holding GmbH, Exactech Inc., Collagen Matrix Inc., Evonik Industries AG, and Koninklijke DSM N.V. (DSM Biomedical B.V.). North America was the largest region in the orthopedic biomaterials market in 2022. Western Europe was the second largest region in the global orthopedic biomaterials market report. The regions covered in the global orthopedic biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the orthopedic biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The orthopedic biomaterials market consists of sales of glass-ceramic and bioactive glasses and calcium phosphate cements. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global orthopedic biomaterials market is segmented - 1) By Material Type: Ceramics & Bioactive Glasses, Calcium Phosphate Cements, Polymers, Metal, Composites 2) By Application: Orthopedic Implants, Joint Replacement/Reconstruction, Bio-Resorbable Tissue Fixation, Orthobiologics, Viscosupplementation 3) By End-User: Hospitals, Clinics, Other End-Users

An implantable biomaterial is a natural or synthetic material that is used in medical applications to support, enhance, or replace damaged tissue or a biological structure. The main materials in the implantable biomaterials are the materials such as metallic, ceramic, polymers, and natural. Metallic implants in implantable biomaterials refer to the component that is widely selected for orthopedic prosthesis over polymeric biomaterials and traditional ceramic materials and is used for the enhancement of biological activities. The various applications include dental, cardiovascular, ophthalmology, orthopedic, and others. These are used in hospitals, ambulatory surgical centres, and specialty clinics. The implantable biomaterials market research report is one of a series of new reports from The Business Research Company that provides implantable biomaterials market statistics, including implantable biomaterials industry global market size, regional shares, competitors with a implantable biomaterials market share, detailed implantable biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the implantable biomaterials industry. This implantable biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable biomaterials market grew from $113.64 billion in 2022 to $127.97 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable biomaterials market is expected to grow from $198.4 billion in 2027 at a CAGR of 11.6%. The allocation of funds by government organizations in the development of new biomaterials [SR1] contributed to the implantable biomaterials market growth. For instance, Drexel University granted USD 200,000 to the National Science Foundation for research on biomaterial-mediated control over macrophage behavior that affects biomaterial vascularization. The support from government organizations in the development of new biomaterials will drive the implantable biomaterials market. Limitations of biomaterial-based products are a major challenge for the implantable biomaterials market. For instance, metal biomaterials can corrode due to chemical reactions within the body such as enzymes and acids or it can also cause some metal ion toxicity in the body. Polymer biomaterial implants have intensive interaction with the body and can lead to wear and tear and can absorb the important nutrients and water from the blood. Some biomaterial implants can also minimize bone ingrowth or sometimes, implants can loosen over time and become dislodged. These reactions that biomaterials have with the body restrain their use thereby negatively impacting the implantable biomaterials market's growth. Major companies in the implantable biomaterials market are implementing 3D printing of biomaterials in manufacturing. For instance, Evonik is producing 3D printable biomaterials for medical technology that are used for manufacturing medical implants with permanent body contact and temporary body contact line of bioresorbable filaments and powders. Implants with permanent body contact are based on Vestakeep Peek, and with the temporary body, contact is based on Resume. In April 2022, Integer Holdings Corporation, a US-based medical device company, acquired Connemara Biomedical Holdings Teoranta for an undisclosed amount. The acquisition would bring implantable biomaterial technology to Integer’s control and help its growth. Connemara Biomedical Holdings Teoranta is a Ireland-based manufacturer of biomaterials for cardiovascular implants. Major players in the implantable biomaterials market are Evonik Industries AG, Royal DSM, Zimmer Biomet Holdings, Carpenter Technology Corporation, Collagen Matrix, Corbion, BASF SE, Invibio Ltd., and Celanese Corporation. North America was the largest region in the implantable biomaterials market in 2022. Western Europe was the second largest region in the global implantable biomaterials market report. The regions covered in the global implantable biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable biomaterials market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The implantable biomaterial market consists of sales of glass-ceramic and bioactive glasses and calcium phosphate cements. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global implantable biomaterials market is segmented - 1) By Material: Metallic, Ceramic, Polymers, Natural 2) By Application: Dental, Cardiovascular, Ophthalmology, Orthopedic, Other Applications 3) By End-user: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

Polymer biomaterials are inert pharmacological substances made up of natural and synthetic origin. The polymer biomaterials are used for enhancing the functionality of tissues and organs that are damaged in various disease therapies. The main types in the polymer biomaterial are silicone rubber, polyester, polymethyl methacrylate (PMMA), polyethylene (PE), polyvinyl chloride, and others. The silicon rubber in polymer biomaterials refers to the rubber matrix that is lightly cross-linked with a polyacrylamide hydrogel and is used for biological and medical purposes. The various nature includes natural and synthetic. The polymer biomaterials are used in cardiovascular, ophthalmology, dental, plastic surgery, wound healing, tissue engineering, orthopedics, neurological disorders / central nervous systems, and others. The polymer biomaterial market research report is one of a series of new reports from The Business Research Company that provides polymer biomaterial market statistics, including polymer biomaterial industry global market size, regional shares, competitors with a polymer biomaterial market share, detailed polymer biomaterial market segments, market trends and opportunities, and any further data you may need to thrive in the polymer biomaterial industry. This polymer biomaterial market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global polymer biomaterial market grew from $55.96 billion in 2022 to $66.45 billion in 2023 at a compound annual growth rate (CAGR) of 18.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The polymer biomaterial market is expected to grow from $126.74 billion in 2027 at a CAGR of 17.5%. Increasing applications of polymeric biomaterials in tissue engineering are driving the global polymer biomaterials market. Polymers are extensively used in regenerative medicine and tissue engineering due to their flexibility and versatile properties such as tailoring the damaged tissue's physical, chemical, and mechanical properties by modification of functional groups during synthesis, according to the regeneration capability of tissues of the organs. Besides being biodegradable, they offer different geometry and structures, thus meeting the needs of specific tissue engineering applications. These growing applications of polymer biomaterial in tissue engineering are expected to drive the market in the forecast period. Stringent regulatory systems concerning the biocompatibility of polymer biomaterials are expected to limit the global polymer biomaterials market. Although biomaterials undergo rigorous premarket evaluations, considerable adverse events and complications are reported regarding the biocompatibility of polymer biomaterials. Biomaterial implantation may result in immunological and inflammatory reactions due to the induction of cellular and molecular events in the host, which may lead to excessive inflammation, impairment of healing, fibrotic encapsulation, tissue destruction, or even isolation and rejection of the implant. To overcome such adverse immune reactions, stringent regulations are imposed by the regulatory authorities, restricting the market growth. Companies in the polymer biomaterial market are increasingly investing in bioresorbable copolymers for medical devices for better performance and long-term stability. Companies such as Evonik have invested in bioresorbable polymers for use in implantable medical devices. The company's copolymer possesses hydrophobic properties of polylactide and hydrophilic properties of polyethylene glycol enabling the degradation rates up to six times faster with added mechanical strength. This innovation enhances biocompatibility, safety, and performance of implantable products, and is applied in the areas of pediatrics and wound closure to accelerate and ease the healing process and provide long-term stability. In January 2020, Mitsubishi Chemical Corporation completed the acquisition of AdvanSource Biomaterials Corporation for $7.25 million. This acquisition is expected to strengthen Mitsubishi’s position within the medical sector and drive its revenues. AdvanSource Biomaterials is a US-based company that manufactures polymer materials that provide critical characteristics in the design and development of medical devices. These polymer biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. Major players in the polymer biomaterials market are BASF, Corbion, Zimmer Biomet, Royal DSM, Koninklijke DSM, Covestro, Evonik Industries, Starch Medical, Victrex, and W. L. Gore and Associate. North America was the largest region in the polymer biomaterials market in 2022. Western Europe was the second largest region in the global polymer biomaterials market report. The regions covered in global polymer biomaterial market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the polymer biomaterials market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and USA. The polymer biomaterials market consists of sales of PCL, PVDF, PLGA, PVP, and nylon. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global polymer biomaterial market is segmented - 1) By Type: Nylon, Silicone Rubber, Polyester, Polymethyl Methacrylate (PMMA), Polyethylene (PE), Polyvinyl Chloride, Other Types 2) By Application: Cardiovascular, Ophthalmology, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Orthopedics, Neurological Disorders / Central Nervous System, Other Applications 3) By Nature: Natural, Synthetic

Healthcare nanotechnology refers to the area of science that combines nanotechnology with drugs or diagnostic molecules to improve the performance of specific cells or tissues. These materials are produced on a nanoscale level and are safe to inject into the body. Nanotechnologies can greatly enhance medical diagnostics by making them more affordable and practical. The main types of healthcare nanotechnology include organic, inorganic, and carbon-based. Healthcare nanotechnology is used for various diseases such as cardiovascular, oncological, neurological, orthopedic, and infectious diseases. The main applications of healthcare nanotechnology include drug delivery, biomaterials, active implants, and tissue regeneration. The healthcare nanotechnology market research report is one of a series of new reports from The Business Research Company that provides healthcare nanotechnology market statistics, including healthcare nanotechnology industry global market size, regional shares, competitors with healthcare nanotechnology market share, detailed healthcare nanotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare nanotechnology industry. This healthcare nanotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global healthcare nanotechnology market size will grow from $276.91 billion in 2022 to $316.3 billion in 2023 at a compound annual growth rate (CAGR) of 14.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The healthcare nanotechnology market size is expected to grow to $556.04 billion in 2027 at a CAGR of 15.1%. Increasing cancer disease cases are expected to propel the growth of the healthcare nanotechnology market. Nanotechnology is a promising mode of cancer treatment. This improving field of medical research can be used to discover better-personalized treatments for many diseases, including cancer. Globally, the prevalence of cancer is increasing. For instance, according to Globocan, in 2020, global cancer cases increased to 19.3 million cases and 10 million cancer deaths. Therefore, the increasing cancer disease cases are driving the growth of the healthcare nanotechnology market. Strategic collaboration between companies is a key trend gaining popularity in the healthcare nanotechnology market. Companies involved in healthcare nanotechnologies are undergoing partnerships and collaboration to develop new technologies and products. For instance, in July 2020, Nanowear, a US-based developer of a nanosensor technology for medical conditions and chronic disease, announced a partnership with Hackensack Meridian Health Systems. Their aim is to monitor confirmed or suspected COVID-19 patients with Nanowear’s cloth-based nanosensors, which can detect physiological and biomarker changes. Hackensack Meridian Health Systems is a US-based health care chain specializing in academic centers, acute care facilities, and research hospitals. In October 2020, Johnson & Johnson, a US-based healthcare company that develops and manufactures various pharma products, announced the acquisition of Momenta Pharmaceuticals for $6.5 billion. With this acquisition, Johnson & Johnson aims to further advance patient care in autoantibody-driven diseases. Momenta Pharmaceuticals is a UK-based company involved in biotechnology with an innovative scientific platform focused on discovering and developing novel biologic therapeutics. Major players in the healthcare nanotechnology market are Pfizer Inc, Johnson & Johnson, Abbott Laboratories, Celgene Corporation, Merck & Company Inc.,, UCB (Union Chimique Belge) S.A, Teva Pharmaceutical Industries Ltd, Sanofi SA, Taiwan Liposome Company Ltd, GE Healthcare, Mallinckrodt plc, Leadiant Biosciences. North America was the largest region in the healthcare nanotechnology market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the healthcare nanotechnology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Healthcare Nanotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The healthcare nanotechnology market includes revenues earned by entities by targeting tumors, in drug delivery systems, and improving medical imaging. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global healthcare nanotechnology market is segmented - 1) By Disease: Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases 2) By Type: Organic, Inorganic, Carbon-Based 3) By Application: Drug Delivery, Biomaterials, Active Implants, Tissue Regeneration

The biomaterials refer to manmade substances that can be utilized to support tissues or structures in the body. These are natural or synthetic materials that are used in medical applications to support, enhance, or replace damaged tissue or a biological function. The main types of biomaterials are metallic biomaterial, polymeric biomaterials, natural biomaterials and ceramics. The metallic biomaterials are stainless steels, titanium alloys, and cobalt alloys used to provide internal support to biological tissues. The metallic biomaterials are manmade systems that are utilized in joint replacements, dental implants, orthopedic fixations, and stents to offer internal support to biological tissues. Biomaterials have a wide application in cardiovascular, orthopedic, ophthalmology, dental, plastic surgery, wound healing, tissue engineering and neurological/central nervous system and are used in hospitals and clinics, ambulatory surgical centers and other end users. The biomaterials market research report is one of a series of new reports from The Business Research Company that provides biomaterials market statistics, including biomaterials industry global market size, regional shares, competitors with a biomaterials market share, detailed biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the biomaterials industry. This biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global biomaterials market size grew from $104.36 billion in 2022 to $119.95 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biomaterials market size is expected to grow to $219.79 billion in 2027 at a CAGR of 16.3%. The rising incidence of cardiovascular diseases is driving the growth of the biomaterials market. Cardiovascular disorders are caused by high blood pressure, smoking, high cholesterol, inactivity, and other factors. The increase in the prevalence of cardiovascular disorders is mainly due to noncontagious diseases like diabetes, chronic respiratory illness, and heart attacks due to hypertension. Biomaterials such as heart valves, cardiopulmonary bypass system, stents, vascular grafts, complete artificial heart, and pacemakers are used as a healing mechanism for damaged and diseased heart tissue. For instance, in October 2022, according to a report shared by The Centers for Disease Control and Prevention, a US-based national public health agency, the main cause of death in the United States for men, women, and members of the majority of racial and ethnic groups is heart disease. In the United States, heart disease caused approximately 697,000 fatalities in 2020, or one death out of every five. In the United States, a cardiovascular disease death occurs every 34 seconds. Therefore, the rising incidence of cardiovascular diseases will increase the demand for biomaterials. The strategic partnership is a key trend gaining popularity in the biomaterials market. Key companies are focusing on partnerships to develop new implants and combination devices based on biomaterials by leveraging each other’s expertise, technology, and resources. These partnerships are also focused on enhancing the adoption of biomaterials. Such partnerships enable companies to gain a competitive edge in the market and increase revenue. For instance, in December 2020, DuPont, a US-based producer of biomaterials, partnered with a Finland-based global chemicals company, Kemira Oyj, for development and commercialization of new breakthrough biomaterials. In the partnership, Kemira's role would be to jointly develop and market a variety of novel biobased and biodegradable goods across Kemira's major product lines. As per the conditions of the partnership, Kemira will have access to the engineered polysaccharide platform, a novel and distinctive biomaterial technology from DuPont. Through this partnership, the two parties will soon be able to sell a variety of novel, biobased, and biodegradable products in their respective core industries. In January 2021, Evonik Industries AG, a German specialty chemicals company acquired the LACTEL business of biodegradable polymers from DURECT Corporation for $15 million. With this acquisition, Evonik aims to expand in fast-growing markets such as biomaterials for tissue engineering, advanced drug delivery, and the 3D printing of implantable medical devices. DURECT Corporation is a US-based specialty pharmaceutical company. Major players in the biomaterials market are Carpenter Technology Corporation, Corbion NV, Evonik Industries, Royal DSM, Berkeley Advanced Biomaterials, BASF SE, Zimmer Biomet, Johnson and Johnson, Invibio, Medtronic, Organogenesis Holdings Inc., Stryker, Wright Medical Group NV, 3M Healthcare, AdvanSource Biomaterials Corporation, Baxter, Covestro, Cam Bioceramics BV, Celanese Corporation, CoorsTek Inc., CeramTec, Victrex plc and Collagen Matrix Inc., North America was the largest region in the biomaterials market in 2022. The regions covered in the biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biomaterials market consists of sales of metals, polymers, and composites. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global biomaterials market is segmented - 1) By Type: Metallic Biomaterial, Polymeric Biomaterials, Natural Biomaterials, Ceramics 2) By Application: Cardiovascular, Orthopedic, Ophthalmology, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Neurological/Central Nervous System 3) By End Use: Hospitals And Clinics, Ambulatory Surgical Centers, Other End Users